Iovance Biotherapeutics (IOVA) Misses Q4 EPS by 1c

Iovance Biotherapeutics (NASDAQ: IOVA) reported Q4 EPS of ($0.18), $0.01 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $86.71 million versus the consensus estimate of $82.03 million.

For earnings history and earnings-related data on Iovance Biotherapeutics (IOVA) click here.

You May Also Be Interested In

• Hawaiian Electric trades at 8.8x P/E, but wildfire risk clouds value case
• C3 AI (AI) call put ratio 1.6 calls to 1 put into quarter results
• Sonos launches OS 27 with AI control and two new products